Study Stopped
low recruitment
Evaluation of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer
Randomized Phase III Trial Evaluating the Impact of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer
1 other identifier
interventional
61
1 country
35
Brief Summary
GYNECO 02 hypothesis is that hysterectomy reduces the possibility of local or loco-regional relapse, especially in patient with a reduced metastatic risk and who received a local chemoradiation therapy with an increase of radiotherapy doses (45 grays).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_3
Started May 2003
Typical duration for phase_3
35 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2003
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2006
CompletedFirst Submitted
Initial submission to the registry
May 5, 2011
CompletedFirst Posted
Study publicly available on registry
June 1, 2011
CompletedJune 1, 2011
May 1, 2011
May 5, 2011
May 30, 2011
Conditions
Outcome Measures
Primary Outcomes (1)
Relapse free survival
There is a follow-up period of 3 years.
from randomization to relapse or last contact (up to 3 years)
Secondary Outcomes (1)
Overall Survival
From randomisation to death or last contact (up to 3 years)
Study Arms (2)
with hysterectomy
EXPERIMENTALwithout hysterectomy
NO INTERVENTIONInterventions
Eligibility Criteria
You may qualify if:
- operable Stage IB2/II Cervical Cancer
- adenocarcinoma, squamous cell or adenosquamous carcinoma
- Patient between 18 and 70 years old
- No lombo-aortic lymph node invasion at baseline
- Previous 45 grays external pelvic radiation with concomitant chemotherapy (cisplatin 40 mg/m2/week corresponding to 5 cycles)
- Followed by a 15 grays utero-vaginal brachytherapy, eventually combined with a 6th cycle of chemotherapy (cisplatin 40 mg/m2)
- with a pelvic boost if lymph node or parametrial invasion
- No macroscopic residual tumor after 6 to 8 weeks after brachytherapy.
You may not qualify if:
- Other tumor histology (neuro-endocrine)
- Stage \> II (FIGO 1995) at baseline
- Patient with remaining cervical cancer (after sub-total hysterectomy)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- UNICANCERlead
Study Sites (35)
Clinique Axium
Aix-en-Provence, 13100, France
Polyclinique du Parc Rambot
Aix-en-Provence, 13100, France
Clinique Sainte Thérèse de l'enfant Jésus
Amiens, 80039, France
Centre Hospitalier Universitaire
Amiens, 80054, France
Centre Paul Papin
Angers, 49033, France
Centre Hospitalier de Beauvais
Beauvais, 60021, France
Institut Bergonié
Bordeaux, 33076, France
Centre Hospitalier Nord Deux-Sèvres
Bressuire, 79302, France
Centre Hospitalier Universitaire de Brest
Brest, 29609, France
Centre Hospitalier Intercommunal
Créteil, 94010, France
Centre Georges-François Leclerc
Dijon, 21034, France
Centre Hospitalier de Fontainebleau
Fontainebleau, 77305, France
Hôpital Hotel-Dieu
Lyon, 69288, France
Centre Hospitalier Edouard Herriot
Lyon, 69437, France
Centre Hospitalier Lyon Sud
Lyon, 69495, France
Institut paoli Calmettes
Marseille, 13273, France
Centre Hospitalier Régional Universitaire La Timone
Marseille, 13385, France
Hôpital de la conception
Marseille, 13385, France
Centre Hospitalier Régional Universitaire Hôpital Nord
Marseille, 13915, France
Centre Hospitalier Universitaire - Hôpital Arnaud de Villeneuve
Montpellier, 34295, France
Centre Val d'Aurelle-Paul Lamarque
Montpellier, 34298, France
Centre hospitalier des Pays de Morlaix
Morlaix, 29205, France
Centre René Gauducheau
Nantes, 44805, France
Hôpital de la Source
Orléans, 45067, France
Hôpital des Diaconnesses
Paris, 75571, France
Hôpital Européen Georges Pompidou
Paris, 75908, France
Centre Hospitalier Universitaire Jean Bernard
Poitiers, 86021, France
Polyclinique de Courlancy
Reims, 51100, France
Clinique Mutualiste de la Sagesse
Rennes, 35013, France
Centre Universitaire Hospitalier- Hôpital Sud
Rennes, 35203, France
Centre Henri Becquerel
Rouen, 76038, France
Centre René Huguenin
Saint-Cloud, 92210, France
Institut Claudius Régaud
Toulouse, 31052, France
Centre Hospitalier Bretonneau
Tours, 37044, France
Institut Gustave Roussy
Villejuif, 94805, France
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Philippe MORICE, Pr
Gustave Roussy, Cancer Campus, Grand Paris
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
May 5, 2011
First Posted
June 1, 2011
Study Start
May 1, 2003
Study Completion
November 1, 2006
Last Updated
June 1, 2011
Record last verified: 2011-05